• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

    9/3/24 7:00:00 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary
    Get the next $ASH alert in real time by email

    Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire").

    Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydration, joint health, women's and men's health, and cardiovascular health. The Company also provides custom formulation and contract manufacturing services to the nutrition market, handling everything from formula design and ingredient sourcing to finished product manufacturing.

    Pharmachem announced that Maurice Murphy, an Operating Partner with Turnspire, has been named Executive Chairman of the Board. Mr. Murphy was most recently CEO of UPG, a former Turnspire portfolio company, where he led the company's transformation into a customer-focused industry leader.

    "I am thrilled to join a company as customer-centric and innovation-driven as Pharmachem," said Mr. Murphy. "As an independent company with Turnspire's support, we will be able to accelerate the Company's growth through close partnerships with high-caliber customers and investments in new capabilities."

    Pharmachem also announced the appointment of Jeff Rogers, a seasoned executive in the ingredients space, as Interim Chief Executive Officer. Mr. Rogers was most recently President and Chief Operating Officer of Niacet, where he was responsible for leading the company's commercial and manufacturing operations. He has also held leadership roles at Ashland, Lonza, AkzoNobel, and National Starch.

    "I am excited to join the Pharmachem team and build on its rich legacy as an innovator in the nutraceuticals space," said Mr. Rogers. "We look forward to partnering with our valued customers to develop new and creative custom formulations and proprietary products. We are excited to leverage our vast capabilities to pursue a wide array of attractive growth opportunities while continuing to provide the highest-quality service for our customers."

    In addition to Mr. Murphy and Mr. Rogers, Pharmachem will be led by members of its current management team.

    Pharmachem was the original name of the Company and was used from its founding in 1972 until 2017. As Pharmachem becomes an independent company again, the team is excited to leverage its legacy name while adding "Innovations" to reflect its path forward as an agile, capabilities-driven business.

    About Pharmachem Innovations

    Pharmachem Innovations is a leader in the development and production of nutraceuticals ingredients, providing both proprietary nutrition ingredients and custom formulation services to nutritional product companies.

    About Turnspire Capital Partners

    Turnspire Capital Partners invests in high-quality businesses that have reached strategic, financial or operational inflection points and stand to benefit from our hands-on, operationally focused approach. Turnspire's investment philosophy is predicated on creating value through operational improvements rather than through financial leverage. Turnspire strives to make each of its portfolio companies best-in-class in their respective industry niche, and then to grow the businesses through organic initiatives or strategic acquisitions. For additional information, please visit www.turnspirecap.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240903868329/en/

    Get the next $ASH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASH

    DatePrice TargetRatingAnalyst
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    3/26/2025$68.00 → $71.00Neutral → Overweight
    Analyst
    3/5/2025Buy → Neutral
    Seaport Research Partners
    8/8/2024$90.00 → $89.00Underweight → Neutral
    JP Morgan
    4/11/2024$100.00 → $112.00Equal Weight → Overweight
    Wells Fargo
    3/14/2024$100.00 → $126.00Hold → Buy
    Jefferies
    3/1/2024$108.00Outperform
    Wolfe Research
    6/29/2023Outperform → In-line
    Evercore ISI
    More analyst ratings

    $ASH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Valvoline Inc. Announces Kevin Willis as Chief Financial Officer

      Valvoline Inc. announces that Kevin Willis will become the Company's next Chief Financial Officer (CFO), effective May 19, 2025Current CFO, Mary Meixelsperger, whose planned retirement was announced October 2024, will remain with the company through a transition periodLEXINGTON, Ky., May 8, 2025 /PRNewswire/ -- Valvoline Inc. (NYSE:VVV), the quick, easy, trusted leader in preventive automotive maintenance, today announced that Kevin Willis will succeed Mary Meixelsperger as Valvoline Inc.'s Chief Financial Officer effective May 19. Willis brings significant public company experience to Valvoline including capital markets management, financial systems integrations, and operating efficiency im

      5/8/25 6:45:00 AM ET
      $ASH
      $VVV
      Specialty Chemicals
      Consumer Discretionary
      Major Chemicals
      Industrials
    • Ashland board authorizes quarterly dividend

      WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock which represents a 2.5 percent increase from the previous quarter. The dividend will be payable on June 15, 2025, to stockholders of record at the close of business on June 1, 2025. As of April 30, 2025, there were 45,696,225 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of

      5/6/25 5:15:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland announces executive leadership changes

      WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

      5/5/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ashland Inc.

      SC 13G - ASHLAND INC. (0001674862) (Subject)

      11/12/24 11:54:03 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Ashland Inc.

      SC 13G/A - ASHLAND INC. (0001674862) (Subject)

      7/10/24 1:14:41 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

      SC 13D/A - ASHLAND INC. (0001674862) (Subject)

      4/25/24 4:15:12 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kulkarni Ashish K converted options into 1,032 shares (SEC Form 4)

      4 - ASHLAND INC. (0001674862) (Issuer)

      5/8/25 4:30:05 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Director Chattopadhyay Sanat

      4 - ASHLAND INC. (0001674862) (Issuer)

      4/1/25 5:00:05 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Director Bishop Steven D

      4 - ASHLAND INC. (0001674862) (Issuer)

      4/1/25 5:00:04 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ashland downgraded by Wells Fargo

      Wells Fargo downgraded Ashland from Overweight to Equal Weight

      5/1/25 3:02:01 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland upgraded by Analyst with a new price target

      Analyst upgraded Ashland from Neutral to Overweight and set a new price target of $71.00 from $68.00 previously

      3/26/25 7:45:24 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland downgraded by Seaport Research Partners

      Seaport Research Partners downgraded Ashland from Buy to Neutral

      3/5/25 7:22:09 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Financials

    Live finance-specific insights

    See more
    • Ashland board authorizes quarterly dividend

      WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock which represents a 2.5 percent increase from the previous quarter. The dividend will be payable on June 15, 2025, to stockholders of record at the close of business on June 1, 2025. As of April 30, 2025, there were 45,696,225 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of

      5/6/25 5:15:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland reports second quarter fiscal 2025 results and revises full-year outlook

      Sales of $479 million, down 17 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), nutraceuticals and Avoca portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $67 million or 12 percent versus the prior-year quarter. Excluding these initiatives, sales declined five percent.Income from continuing operations of $30 million, or $0.63 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $46 million, or $0.99 per diluted shareNet income of $31 million, or $0.65 per diluted shareAdjusted EBITDA of $108 million, down 14 percent f

      4/30/25 5:01:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland sets date for second-quarter fiscal 2025 earnings release and conference call webcast

      WILMINGTON, Del., April 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its second-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Wednesday, April 30, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Thursday, May 1. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerKevin Willis, senior vice president and chief financia

      4/17/25 6:30:00 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

      4 - ASHLAND INC. (0001674862) (Issuer)

      2/3/25 4:30:05 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SVP and GM, Life Sciences Assis Alessandra Faccin bought $201,600 worth of shares (3,150 units at $64.00) (SEC Form 4)

      4 - ASHLAND INC. (0001674862) (Issuer)

      2/3/25 4:30:03 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    SEC Filings

    See more
    • Ashland Inc. filed SEC Form 8-K: Leadership Update

      8-K - ASHLAND INC. (0001674862) (Filer)

      5/5/25 5:00:09 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 10-Q filed by Ashland Inc.

      10-Q - ASHLAND INC. (0001674862) (Filer)

      5/1/25 4:04:10 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ASHLAND INC. (0001674862) (Filer)

      4/30/25 5:14:56 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    Leadership Updates

    Live Leadership Updates

    See more
    • Ashland announces executive leadership changes

      WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

      5/5/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

      Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu

      9/3/24 7:00:00 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

      Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio

      9/3/24 7:00:00 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary